Zhenyang Wang

Dr. Zhenyang Wang


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 April 2026 in Genes
Verified
Journal Article
Open access
PDF file
ZWZhenyang Wang
Zhenyang Wang
YCYongqin Chen
Yongqin Chen
YYYuxuan Yang
Yuxuan Yang
BXBiteng Xu
Biteng Xu
XJXiejia Jiao
Xiejia Jiao
LQLei Qi
Lei Qi
Background: This study investigates the role of N6-methyladenosine (m6A) regulators in osteoporosis (OP) and their interplay with the immune microenvironment, aiming to identify potential m6A-related biomarkers for OP risk assessment and treatment. Methods: Transcriptomic data from GEO datasets were analyzed for differential expression of 22 m6A regulators and immune infiltration patterns. Consensus clustering and m6Ascore grouping defined molecular subtypes, while machine learning algorithms identified potential biomarkers, leading to the construction and validation of a nomogram. Experimental validation involved peripheral blood monocytes (PBMCs) transcriptome sequencing and Western blot of bone tissue. Results: FTO, HNRNPC, and METTL4 were upregulated, while CBLL1 and YTHDF2 were downregulated in OP, with two distinct m6A modification patterns and immune phenotypes identified. METTL4, HIRA, MATN4, and YTHDF2 were selected as potential biomarkers, and the nomogram demonstrated favorable predictive performance in training and external datasets. Single-cell RNA sequencing confirmed the cellular distribution of these biomarkers. HIRA heterogeneity in Marrow Mesenchymal Stem Cells (BMSCs) was associated with distinct cell–cell communication patterns. Transcriptome sequencing confirmed HIRA RNA downregulation in OP PBMCs, and Western blot verified decreased HIRA protein in OP bone tissue. Conclusions: This study establishes a potential m6A-related biomarker signature for OP and provides multi-level experimental evidence that HIRA is a consistently downregulated biomarker, linking epigenetic modification to immune dysregulation in osteoporosis.